Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR)

Pfizer, NCT05011513, EPIC-SR, NCT05011513, Jun 2022
Mortality 67% improvement lower risk ← → higher risk Hospitalization 52% Progression 4% Time to sustained alle.. 8% Change in viral load 4% Paxlovid for COVID-19  EPIC-SR  EARLY TREATMENT RCT Is early treatment with paxlovid beneficial for COVID-19? Double-blind RCT 1,288 patients in multiple countries (Aug 2021 - Jul 2022) Improved viral clearance with paxlovid (p=0.039) c19early.org Pfizer, NCT05011513, June 2022 0 0.5 1 1.5 2+ RR
Results for the terminated and unpublished (until April 2024) EPIC-SR trial.
Important missing comments or errors? Let us know.
risk of death, 67.0% lower, RR 0.33, p = 0.49, treatment 0 of 654 (0.0%), control 1 of 634 (0.2%), NNT 634, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 28.
risk of hospitalization, 51.5% lower, RR 0.48, p = 0.20, treatment 5 of 654 (0.8%), control 10 of 634 (1.6%), NNT 123, day 28.
risk of progression, 3.8% lower, RR 0.96, p = 0.21, treatment 494 of 654 (75.5%), control 498 of 634 (78.5%), NNT 33, day 28.
relative time to sustained alleviation, 7.7% lower, relative time 0.92, p = 0.16, treatment mean 12.0 (±13.0) n=654, control mean 13.0 (±12.8) n=634.
relative change in viral load, 3.9% better, RR 0.96, p = 0.04, treatment mean 5.46 (±1.84) n=654, control mean 5.25 (±1.89) n=634, day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pfizer et al., 14 Jun 2022, Double Blind Randomized Controlled Trial, multiple countries, preprint, 1 author, study period 25 August, 2021 - 25 July, 2022, trial NCT05011513 (history) (EPIC-SR).
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0